Corticosteroid Ocular Complications

The Steroid Responder Phenomenon

Not every eye reacts to topical corticosteroids the same way. Individuals who develop a significant intraocular pressure rise after topical corticosteroid exposure are termed steroid responders. The IOP elevation is typically evident within weeks of starting therapy and reflects heightened sensitivity of the trabecular meshwork to corticosteroid-induced outflow resistance. This trait is more common in patients who already have primary open-angle glaucoma or a family history of glaucoma — a detail worth asking about before starting anyone on a prolonged topical steroid taper.

Steroid-Induced Ocular Hypertension

The mechanism behind steroid-induced IOP elevation is specific: corticosteroids cause accumulation of glycosaminoglycans and altered extracellular matrix within the trabecular meshwork itself, increasing resistance to aqueous outflow. This is a distinct mechanism from pupillary block or a hypersecretion-based glaucoma — the problem is downstream, at the drainage angle, not at aqueous production or the angle anatomy. Because the effect is dose- and duration-dependent and can occur with topical, periocular, or even intravitreal steroid exposure, IOP needs to be monitored throughout any course of ocular corticosteroid therapy, not just checked once at baseline.

Not every route of corticosteroid exposure carries the same risk. Ocular routes, especially periocular and intravitreal depots, produce the highest rates of clinically significant IOP elevation because the drug sits close to the trabecular meshwork at a sustained, concentrated dose. Systemic corticosteroids given orally or by other non-ocular routes carry a comparatively lower risk. Topical steroid-induced IOP elevation is usually reversible. Pressure typically climbs within three to six weeks of starting therapy and falls back toward baseline within a few weeks after the drug is stopped, unlike primary open-angle glaucoma, which does not resolve on its own.

Posterior Subcapsular Cataract

Chronic use of topical corticosteroids most characteristically causes a posterior subcapsular cataract. The proposed mechanism is that steroids bind lens epithelial cell proteins, causing abnormal migration and differentiation of those cells toward the posterior pole of the lens. This location is disproportionately visually disabling for its size, because it sits directly in the path of convergent light rays converging toward the retina — a small posterior subcapsular opacity can cause outsized glare and reading difficulty compared to an equivalently-sized nuclear or cortical change.

Fungal Keratitis Risk

Prolonged topical steroid use suppresses local immune defenses and promotes fungal proliferation, making fungal keratitis a recognized and often devastating complication — particularly after keratoplasty or corneal trauma involving organic material, where a fungal inoculum may already be present. A corneal infiltrate developing in a patient on chronic topical steroids after corneal surgery should raise fungal keratitis on the differential, not just bacterial or sterile inflammation, since a reflexive increase in steroid dosing would make a fungal process worse rather than better.

Choosing a Lower-Risk Topical Steroid: Loteprednol

Not all topical corticosteroids carry the same IOP risk. Loteprednol etabonate is preferred for chronic anterior segment inflammation specifically because of its comparatively lower propensity to elevate intraocular pressure. It's an ester-based corticosteroid that is rapidly metabolized to inactive metabolites after exerting its anti-inflammatory effect at the ocular surface, in contrast to ketone-based steroids like prednisolone acetate or dexamethasone, which remain active longer and drive more sustained trabecular meshwork exposure. This "soft steroid" profile makes loteprednol a common choice when a patient needs an extended topical steroid course and is at elevated risk of becoming a steroid responder.

Related Topics

Continue exploring Uveitis & Ocular Immunology: